News Sentiment

ELVN sentiment intelligence

Enliven Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 55 Balanced news tone 56 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 51.09 Week of 10 Jul 2026

Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+2.5% over one week, +10.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Enliven Therapeutics stock hits 52-week high at 52.47 USD

Market Reaction

Balanced read

65/100 confidence

Primary event Market update 82/100 classification

One-week reaction 2.5% Price confirming higher

Trend fit Trend active 10.8% over four weeks

Fair value 126.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 15

Neutral 34

Negative 7

Relevance

Why the article matched

Direct first

Direct company coverage 48

Industry context 8

Sector context 0

Sources

Coverage mix

Publishers

Market source 12

Stock Titan 12

Investing.com 6

PR Newswire 6

TradingView 4

MT Newswires 3

Investing.com Canada 2

simplywall.st 2

Event Lens

What the news is about

Classified themes

Market update 34

Earnings 11

Analyst action 7

Deals and strategy 4

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-56 of 56

Stock Titan Direct company coverage

Polar Capital (NASDAQ: ELVN) reports 8.46% stake in Enliven Therapeutics

Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have jointly reported an 8.46% beneficial ownership stake in Enliven Therapeutics (NASDAQ: ELVN). This stake amounts to 5,056,807 shares of common stock, based on Enliven Therapeutics'

Tone: Neutral 50/100
Event: Deals and strategy
Published: 22 Jun 2026 13:40
Source: Stock Titan

Stock Titan Direct company coverage

ELVN (Nasdaq) selling holders report proposed sale, recent 272,322-share disposition

Tone: Neutral 50/100
Event: Market update
Published: 22 Jun 2026 07:00
Source: Stock Titan

Stock Titan Direct company coverage

OrbiMed funds trim Enliven Therapeutics (ELVN) stake with 281,408-share sale

Tone: Neutral 50/100
Event: Deals and strategy
Published: 17 Jun 2026 07:00
Source: Stock Titan

MT Newswires Direct company coverage

Enliven Therapeutics Closes Upsized $460 Million Public Offering

Tone: Neutral 50/100
Event: Market update
Published: 15 Jun 2026 21:01
Source: MT Newswires

PR Newswire Direct company coverage

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Tone: Neutral 50/100
Event: Market update
Published: 15 Jun 2026 07:00
Source: PR Newswire

Stock Titan Direct company coverage

Biotech Enliven just raised $460M in stock and warrants

Tone: Neutral 50/100
Event: Market update
Published: 15 Jun 2026 07:00
Source: Stock Titan

Stock Titan Direct company coverage

[144] Enliven Therapeutics, Inc. SEC Filing

Tone: Neutral 50/100
Event: Market update
Published: 15 Jun 2026 07:00
Source: Stock Titan

Market source Direct company coverage

Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial

Tone: Neutral 50/100
Event: Market update
Published: 13 Jun 2026 07:00
Source: Market source

PR Newswire Direct company coverage

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

Tone: Positive 66/100
Event: Market update
Published: 11 Jun 2026 07:00
Source: PR Newswire

Stock Titan Direct company coverage

Biotech Enliven prices ~$400 million stock and warrant sale

Tone: Neutral 50/100
Event: Market update
Published: 11 Jun 2026 07:00
Source: Stock Titan

PR Newswire Direct company coverage

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Tone: Neutral 50/100
Event: Market update
Published: 11 Jun 2026 07:00
Source: PR Newswire

PR Newswire Direct company coverage

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Tone: Neutral 50/100
Event: Market update
Published: 11 Jun 2026 07:00
Source: PR Newswire

Market source Direct company coverage

A Look At Enliven Therapeutics (ELVN) Valuation As ENABLE Trial Data Update Nears

Tone: Neutral 50/100
Event: Market update
Published: 07 Jun 2026 07:00
Source: Market source

simplywall.st Industry context

There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings

Tone: Negative 34/100
Event: Earnings
Published: 15 May 2026 07:00
Source: simplywall.st

Market source Industry context

Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings

Tone: Neutral 50/100
Event: Earnings
Published: 14 May 2026 07:00
Source: Market source

simplywall.st Industry context

Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results

Tone: Positive 66/100
Event: Earnings
Published: 11 May 2026 07:00
Source: simplywall.st

Market source Industry context

Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00

Tone: Neutral 50/100
Event: Earnings
Published: 11 May 2026 07:00
Source: Market source

PR Newswire Direct company coverage

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Tone: Neutral 50/100
Event: Earnings
Published: 07 May 2026 07:00
Source: PR Newswire

Market source Industry context

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 25 Apr 2026 07:00
Source: Market source

Market source Industry context

Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)

Tone: Neutral 50/100
Event: Earnings
Published: 21 Apr 2026 07:00
Source: Market source

Market source Direct company coverage

Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market

Tone: Positive 66/100
Event: Market update
Published: 17 Apr 2026 07:00
Source: Market source

Market source Direct company coverage

Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum

Tone: Positive 66/100
Event: Market update
Published: 29 Mar 2026 07:00
Source: Market source

TradingView Industry context

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

Tone: Neutral 50/100
Event: Earnings
Published: 29 Mar 2026 07:00
Source: TradingView

Stocktwits Direct company coverage

Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio

Tone: Neutral 50/100
Event: Deals and strategy
Published: 25 Mar 2026 07:00
Source: Stocktwits

Market source Direct company coverage

Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’

Tone: Neutral 50/100
Event: Market update
Published: 25 Mar 2026 07:00
Source: Market source

PR Newswire Direct company coverage

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Tone: Neutral 50/100
Event: Market update
Published: 16 Jun 2025 07:00
Source: PR Newswire